T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Summary

T2 Biosystems, a leader in sepsis detection, has announced its participation in the Canaccord Genuity MedTech Forum in New York. Scheduled for November 17, 2022, at 2 PM ET, the event will feature a presentation accessible via a live webcast on the company's website.

Known for its innovative T2 Magnetic Resonance technology, T2 Biosystems aims to enhance patient care by enabling faster treatment decisions. The firm offers various diagnostic panels, including T2Dx, T2Bacteria, T2Candida, T2Resistance, and T2SARS-CoV-2, and has several products in development.

LEXINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, New York.

Management is scheduled to present on Thursday, November 17, 2022, at 2pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com.

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx^® Instrument, the T2Bacteria^® Panel, the T2Candida^® Panel, the T2Resistance^® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR^®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ Panel, the T2Cauris™ Panel, and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers.

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406

FAQ

What is T2 Biosystems' participation in the Canaccord Genuity Forum 2022?

T2 Biosystems will present at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on November 17, 2022, at 2 PM ET.

How can I access T2 Biosystems' presentation from the Canaccord Genuity Forum?

The presentation will be available via a live and recorded webcast on T2 Biosystems' website.

What products does T2 Biosystems offer for sepsis detection?

T2 Biosystems offers products like the T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, T2Resistance Panel, and T2SARS-CoV-2 Panel.

What technology powers T2 Biosystems' diagnostic products?

T2 Biosystems' diagnostic products are powered by their proprietary T2 Magnetic Resonance technology.

What future products is T2 Biosystems developing?

T2 Biosystems has a pipeline including the T2Biothreat Panel, T2Cauris Panel, and T2Lyme Panel.